Dyadic International prices public offering of 6 million shares

JUPITER, Fla. - Dyadic International, Inc. (NASDAQ:DYAI), a biotechnology company with a market capitalization of $34 million and current trading price of $1.13, announced Thursday the pricing of its underwritten public offering of 6,052,000 shares of common stock, with closing expected on August 1, 2025.

Craig-Hallum Capital Group LLC is serving as the sole managing underwriter for the offering. The biotechnology company plans to use the net proceeds for working capital and general corporate purposes, including product development, sales and marketing.

The offering is being conducted under an effective shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on August 9, 2023, and declared effective on August 25, 2023.

Dyadic International develops proprietary gene expression platforms for producing high-value proteins used in life sciences, food and nutrition, and industrial biotechnology applications. The company’s technology enables the production of recombinant proteins that customers can use to develop more efficient and sustainable products.

The announcement follows the filing of a preliminary prospectus supplement and accompanying prospectus with the SEC describing the offering details.

This information is based on a press release statement issued by the company. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

In other recent news, Dyadic International has announced the commencement of a public offering of common stock shares, with Craig-Hallum Capital Group LLC acting as the sole managing underwriter. Additionally, the company received a notice from the Nasdaq Stock Market regarding a minimum bid price deficiency, as its stock has not maintained the required $1 per share over the past 30 consecutive business days. Dyadic has until January 13, 2026, to regain compliance by achieving a closing price of $1 per share or higher for at least 10 consecutive business days.

In a strategic move, Dyadic will soon operate under the name Dyadic Applied BioSolutions, marking a shift from research to commercial operations. This rebranding emphasizes their focus on non-therapeutic proteins for various applications. The company also announced the appointment of Joe Hazelton as its new President, who will continue to serve as Chief Operating Officer. Hazelton’s appointment is part of a broader strategy to commercialize recombinant protein products across diverse markets.

Furthermore, Dyadic’s shareholders recently approved board proposals at the annual meeting, including the election of Mark A. Emalfarb as a Class III director. These developments highlight the company’s strategic initiatives aimed at fostering growth and addressing market challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.